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Abstract
To further our understanding of the somatic genetic basis of uveal melanoma, we
sequenced the protein-coding regions of 52 primary tumors and 3 liver metastases together
with paired normal DNA. Known recurrent mutations were identified in GNAQ, GNA11,
BAP1, EIF1AX, and SF3B1. The role of mutated EIF1AX was tested using loss of function
approaches including viability and translational efficiency assays. Knockdown of both wild
type and mutant EIF1AX was lethal to uveal melanoma cells. We probed the function of N-
terminal tail EIF1AX mutations by performing RNA sequencing of polysome-associated
transcripts in cells expressing endogenous wild type or mutant EIF1AX. Ribosome occu-
pancy of the global translational apparatus was sensitive to suppression of wild type but not
mutant EIF1AX. Together, these studies suggest that cells expressing mutant EIF1AX may
exhibit aberrant translational regulation, which may provide clonal selective advantage in
the subset of uveal melanoma that harbors this mutation.
Introduction
Uveal melanoma (UM), which accounts for 5% of all melanomas, occurs in the iris, ciliary
body, and choroid of the eye. Approximately 50% of UM patients develop metastatic disease,
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most often to the liver [1]. Primary UM is treated by either enucleation or radiation, while
metastatic UM has no effective therapies and a median survival rate of approximately 6
months [2,3]. Thus, improved treatment of metastatic UM represents an unmet medical need.
Over 80% of UM tumors harbor activating hotspot mutations in GNAQ or GNA11, which
encode alpha subunits of guanine nucleotide binding (G) proteins [4,5]. Mutations at residues
183 and 209 of these proteins result in constitutive downstream signaling to the protein kinase
C, mitogen-activated protein kinase (MAPK), and YAP1 pathways [6–9]. Frequently observed
copy number alterations in UM tumors include loss of a single copy of chromosome 3 (mono-
somy 3), amplification of 8q or 6p, and less frequently 8p gain or 1p, 6q, 16q loss [10,11].
Monosomy 3 is predictive of worse prognosis [12] and often co-occurs with loss of function
mutations in the tumor suppressor BAP1, which is located on chromosome 3 [13]. In addition
to GNAQ, GNA11, and BAP1, recurrent mutations in the splicing factor, SF3B1, as well as the
translation initiation factor, EIF1AX, have been recently characterized in primary UM tumors
[14,15].
Despite these advances, large-scale genome characterization efforts in UM have been lim-
ited by sample size and largely restricted to primary tumors. To expand knowledge of the
somatic genetics of primary and metastatic UM, we sequenced the protein-coding exons of 52
primary tumors and 3 liver metastases derived from 2 patients. We also performed systematic
functional studies focused on EIF1AX, a translation factor recurrently mutated in UM.
Results
Somatic mutations in primary uveal melanoma
Solution-phase hybrid capture and whole exome sequencing (WES) were performed on paired
primary tumor and normal genomic DNA from 61 patients with uveal melanoma (UM).
Tumors were derived from enucleations and represent more advanced stages (Table 1).
101-fold mean target coverage was achieved, with an average of 90% of exonic bases covered
per sample (S1 Table). A subset of 52 tumor/normal pairs passed standard quality control met-
rics, including screening for tumor DNA in normal samples or normal DNA in tumor samples
Table 1. Clinical characteristics of analysis set.
Patients MEEI (N = 23) MDACC (N = 29)
Age at diagnosis (Median; range) 65 (34–89) 62 (23–83)
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(Table 1; S2 Table). The mean somatic mutation rate was 0.46 mutations per megabase (range:
0.031 to 4.00), with an average of 32 coding mutations per patient (Fig 1A; S1 Table). As
expected [15,16], and in contrast to cutaneous melanoma [17], no signature of ultraviolet
(UV) light-induced mutational damage was observed in this UM cohort.
Fig 1. Somatic mutations in primary and metastatic uveal melanoma. (A) The number of synonymous and nonsynonymous mutations
per megabase of DNA sequence for 52 samples, arranged in columns. (B) Mutations in recurrently mutated genes are color-coded and
ordered by significance. (C) Boxplots represent the distributions of allelic fractions observed per sample where the thick line represents 25-
75th percentile, and thin line 5-95th. (D) The percentage of tumor cells (CCF) harboring a given mutation in the primary tumor in comparison
to a metastatic liver sample from the same patient (UM45). (E) As in (D), but comparing a pre-treatment metastatic tumor sample to a post-
treatment metastasis (Trio 2).
https://doi.org/10.1371/journal.pone.0178189.g001
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Chromosomal copy number profiles were also generated using the CapSeg algorithm.
Monosomy at chromosome 3 was observed in 53% of patients (S1 Fig). Consistent with prior
studies [12], the majority of patients who had or went on to develop metastatic disease (11/13)
harbored monosomy 3 (S2 Table). This observation was further validated by Kaplan Meier
analysis, which indicates the expected correlation between monosomy 3 and overall survival
reflecting death from metastatic uveal melanoma or any cause (S2A and S2B Fig). Consistent
with prior analyses, presence of BAP1 mutation, versus either a SF3B1 or EIF1AX mutation
portends a poorer survival (S2C and S2D Fig) [13–16]. As expected [18,19], chromosome 8q
copy gains tended to co-occur with monosomy 3, whereas chromosome 6p copy number gains
did not in this cohort. Other frequent chromosomal changes included chromosome 8p gains
and 1p, 6q, 16q deletions.
To identify significantly mutated genes in UM, we used the MutSigCV algorithm, which
accounts for patient and gene-specific mutation frequency, gene size, and the ratio of synony-
mous to nonsynonymous mutations per gene [17]. Four genes (GNAQ, GNA11, BAP1, and
EIF1AX) were mutated more frequently than expected by chance (Fig 1B). All of these genes
have been previously implicated in UM [4,5,13,15]. We observed 6 mutations in SF3B1 at resi-
dues 625, 662, and 666. Although SF3B1 did not meet the significance threshold in this cohort,
it is a known cancer gene that is also recurrently mutated in UM [14]. Allelic fraction analysis
of called mutations was used to confirm that mutations were present at detectable levels (Fig
1C). All somatic mutations identified in this cohort are available in Supplementary Material
(S3 Table).
Targeted re-sequencing in all 52 tumor/normal pairs independently validated the somatic
mutations identified in these 5 genes. In total, 98.4% of missense/nonsense mutations and
42.9% of small insertions/deletions were validated (S4 Table). Re-sequencing also identified
several additional hotspot mutations in GNAQ (Q209), EIF1AX (G15), and SF3B1 (R625) (Fig
1B). Most of these mutations occurred in regions of low WES sequence coverage, which may
explain why they were not called initially by standard analysis algorithms.
The majority of patients harbored mutually exclusive mutations at residues 209 or 183 of
GNAQ and GNA11 (Fig 1B). One sample (OM-01-110) contained a novel GNAQ mutation,
which harbored two mutations at the same codon (GGA>CTA) resulting in a G48L substitu-
tion. Sequencing reads spanning codon 48 confirmed that these mutations occur in cis. Resi-
due 48 lies within a putative GTP-binding region of GNAQ (http://www.uniprot.org),
suggesting a potential functional role, although its actual effect is unknown.
Mutations in BAP1, EIF1AX, and SF3B1 were almost entirely mutually exclusive of each
other (although most often co-occurring with GNAQ and GNA11 mutations), with only 2 out
of 29 mutant samples harboring alterations in more than one gene. This observation suggests
three predominant genetic classes of UM, defined by these three recurring mutations, and is
supported by data indicating that mutant BAP1 is associated with a worse prognosis, while
EIF1AX and SF3B1mutations indicate a better prognosis [13–15]. Indeed, mutations in
EIF1AX occurred more frequently in Disomy 3 patients (S1 Fig), consistent with prior findings
[15]. No patients with EIF1AX or SF3B1 mutations in this cohort are known to have developed
metastatic disease with the exception of 2 patients that had co-occurring BAP1 mutations (S2
Table). Patient OM-091 harbored missense mutations in both EIF1AX (R13C) and BAP1
(N102K); however, mutant EIF1AX was present at a low allelic fraction (0.051), suggesting a
subclonal event. Sample UM36 contained missense mutations in both BAP1 (G185R; with an
allelic fraction of 0.83) and SF3B1 (K666T; with an allelic fraction of 0.48). The majority of
SF3B1 mutations in UM occur at residue 625, however, lysine 666 is recurrently mutated in
CLL [20]. Both OM-091 and UM36 patients died of metastatic UM (S2 Table), consistent with
Genomic studies of uveal melanoma
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previous studies linking BAP1 mutations in primary UM with a high likelihood of developing
metastatic disease [13].
Somatic mutations in metastatic uveal melanoma
To search for mutated genes in the metastatic setting, we also sequenced tumors from two UM
patients with metastatic disease (UM45 and Trio 2). We utilized the ABSOLUTE algorithm to
assign each somatic mutation a cancer cell fraction (CCF), which corresponds to the percent-
age of tumor cells harboring the genetic event [21]. We then utilized these cancer cell fractions
to identify and compare clonal and subclonal events across distinct tumor samples from the
same patient [22].
For patient UM45, the paired primary enucleated tumor and a single metastatic sample
from a liver biopsy were sequenced. Only 4 clonal missense mutations were present in both
samples (MAN2A1,UHRF1BP1L,HCFC2, CYSLTR2), including the recently described L129Q
alteration in CYSLTR2 [23] (Fig 1D, top right). Phylogenetic analysis using CCFs suggests
these tumors are siblings, which indicates that both the primary and metastatic cells evolved
from a common initial tumor. In this patient, SMARCA4R1192H was enriched in the metastatic
sample compared to the primary tumor (Fig 1D; primary CCF 0, metastatic CCF 0.12). This
observation was further validated using targeted resequencing (S3A Fig). SMARCA4 (or
BRG1) is a catalytic subunit of the SWI/SNF chromatin remodeling complex, which undergoes
somatic mutation in multiple cancers [24]. Although the functional consequence of this muta-
tion within the cellular context of uveal melanoma awaits further study, codon 1192 resides
within the conserved C-terminal helicase domain and is recurrently mutated across multiple
cancer types (http://www.cbioportal.org).
For Trio 2, pre- and post-treatment liver metastases were sequenced, in addition to a nor-
mal sample (no primary tumor sample was available in this case; see S3B Fig for a clinical time-
line). Therapies included an HSP90 inhibitor, a temozolamide/sorafenib combination, and a
MEK inhibitor. Here, the pre-treatment tumor harbored only 4 missense mutations that were
not observed in the post-treatment sample (1 clonal and 3 subclonal), while the post-treatment
sample harbored 25 mutations that were not observed in the pre-treatment sample (1 clonal
and 24 subclonal). Phylogenetic analysis suggests that these samples are siblings, indicating
independent evolution from the same tumor. Seven clonal missense mutations were present in
both samples, including GNA11Q209L, SF3B1E622D, and IQGAP1R893Q (Fig 1E; S5 Table).
IQGAP1 encodes Ras GTPase-activating-like protein, however, it does not harbor Ras-GAP
activity and instead functions as a scaffold protein in several signaling pathways that contribute
to tumorigenic phenotypes including invasion and metastasis [25]. IQGAP1 is not significantly
mutated in any cancer type [26], but rather is frequently overexpressed [25]. All somatic muta-
tions and CCF values determined by ABSOLUTE are available in Supplementary Material (S5
Table).
Mutant and wild type EIF1AX play essential roles in uveal melanoma
cells
The x-linked translation initiation factor, EIF1AX, is the most recently described significantly
mutated gene in UM and has not been functionally characterized in cancer. Consistent with
prior studies [15], we observed recurrent mutations within the N-terminal 15 amino acids of
EIF1AX that co-occur with GNAQ or GNA11 mutations (Fig 2A). This UM clustering pattern
stands in contrast to pan-cancer analyses in which synonymous and non-synonymous muta-
tions were observed throughout the EIF1AX coding region [26], however, in specific cancer
types such as papillary thyroid carcinoma, recurrent mutations localized to the N-terminal tail
Genomic studies of uveal melanoma
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(NTT) were observed [27]. All EIF1AX mutations in our UM cohort were non-synonymous
and localized within the unstructured N-terminal tail (NTT) [28]. In addition, no inactivating
mutations such as nonsense or frameshift mutations were observed. Together, these observa-
tions raise the possibility of a gain-of-function mutational event.
We also identified a homozygous G!A mutation at the start of exon 2 in a single estab-
lished UM cell line (92.1) (S4 Fig). Transcriptome analysis (RNAseq) of 92.1 cells demon-
strated faithful transcription of the G6D missense mutation, without evidence for altered
Fig 2. EIF1AX-regulated growth and translation in uveal melanoma. (A) Distribution of EIF1AX mutations observed in cohort of 52 uveal
melanomas in comparison to other cancer types (as reported by http://www.tumorportal.org). (B) EIF1AX wild type (WT) or mutant (MUT) uveal
melanoma cells were infected with EIF1AX or control shRNAs and cell viability was determined after 6 days using MTS. Percent growth is relative
to shLuc-expressing cells. Error bars represent SD of mean from 3 independent experiments. (C) Immunoblot analysis of EIF1AX protein levels in
shRNA-expressing cells. (D) Polysome profiles of cell lines expressing shRNAs against EIF1AX and Luciferase.
https://doi.org/10.1371/journal.pone.0178189.g002
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mRNA splicing or wild type allele expression (S6A Fig). This finding is consistent with prior
studies demonstrating exclusive expression of mutant EIF1AX mRNA in tumor samples from
both male and female individuals [15]. These data suggest that in female patients, the wildtype
allele is located on the inactivated X chromosome. Also consistent with prior studies [15], the
majority of EIF1AX-mutant tumors in this cohort were male (7/10). However, the 92.1 cell line
containing a homozygous mutation was from a female patient, suggesting poor sequencing of
the inactivated X chromosome or genetic loss of the EIF1AX region. Examination of even
larger cohorts may provide further insight into association of EIF1AX mutations and sex chro-
mosome inactivation.
EIF1AX encodes an essential component of translation initiation [29]. Binding of EIF1AX
to the small ribosomal subunit aids in assembly of the pre-initiation complex (PIC) and facili-
tates mRNA scanning [30–32]. More specifically, the EIF1AX-NTT stimulates PIC formation,
interacts with eIF2 and eIF3, and aids in identifying the initiator codon [33–35]. Therefore,
somatic mutations in the EIF1AX-NTT may result in changes in translational regulation—
either global or specific mRNA effects.
To gain preliminary insights into the function of mutant EIF1AX in UM cells, we used len-
tiviral shRNA knockdown to suppress EIF1AX expression in a panel of UM cell lines, includ-
ing the 92.1 line, which contains an EIF1AXG6D mutation. Expression of EIF1AX shRNAs both
decreased EIF1AX gene expression and impaired UM cell viability (Fig 2B and 2C). Notably,
both EIF1AX-mutant and EIF1AX-wild type UM cell lines exhibited suppressed viability fol-
lowing knockdown, suggesting that EIF1AX may be uniformly essential in UM cells. Based on
these knock down results, EIF1AX-NTT mutations in UM likely do not solely confer loss of
wild type protein function.
In light of these results, we sought to determine if EIF1AX might represent a dependency
across multiple contexts. To assess this, we leveraged Project Achilles dataset 2.4.3 (http://
www.broadinstitute.org/achilles), which consists of large-scale pooled shRNA screening
(>90,000 shRNAs) across 216 cancer cell lines of various lineages [36]. In Project Achilles,
cells were infected with a pool of shRNAs and the relative levels of shRNAs present at 16 popu-
lation doublings was compared to the initial plasmid pool. Those shRNAs selectively depleted
after 16 population doublings may indicate genes that are essential to the viability of the rele-
vant cell lines.
Five shRNAs targeting EIF1AX were present in the Project Achilles dataset. Of these, two
were strongly depleted across all 216 cell lines (S5A Fig, top). Although off-target effects can-
not be entirely ruled out, these 2 shRNAs were also the most effective at suppressing EIF1AX
protein levels (S5B Fig). The magnitude of shRNA depletion was similar to the gene that
encodes ribosomal protein S6 (RPS6), a known essential gene (S5A Fig, bottom). Taken
together, these data are consistent with EIF1AX being universally essential in eukaryotic cells,
and suggest that cancer cells retain this dependency for pre-initiation complex assembly,
growth, and survival, although further functional validation in each cancer type is necessary.
Mutant EIF1AX regulated translation
We next sought to test the hypothesis that EIF1AX-NTT mutations might regulate translation
of a distinct set of transcripts compared to wild type EIF1AX. To investigate this possibility, we
performed polysome profiling of EIF1AX mutant and wild type UM cell lines expressing
shRNAs targeting EIF1AX or Luciferase (shLuc; control). Interestingly, the 80S peak in the
EIF1AX mutant cell line (92.1) showed greater amplitude than that seen in EIF1AX wild type
cells (Omm2.3 and Omm1), raising the possibility that mutant EIF1AX might be associated
with altered protein translation (Fig 2D). RNAi-mediated suppression of EIF1AX expression
Genomic studies of uveal melanoma
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also augmented the 80S peak in all contexts tested, suggestive of reduced polysome formation
and impaired translation initiation (Fig 2D).
EIF1AX-regulated translation was further probed by massively parallel sequencing of total
mRNA and mRNAs from polysome fractions. Sequencing of polysome-associated transcripts
provides a means to identify those mRNAs that may undergo active translation in the cells.
The ratio of polysome-associated mRNA levels to total mRNA levels from input lysate can be
used to calculate the “translational efficiency” of each transcript [37]. RNAseq was used to con-
firm extent of EIF1AX knockdown in shRNA expressing cells (S6B and S6C Fig).
To identify transcripts regulated by EIF1AX, we tested which polysomal/total RNA ratios
were significantly altered upon EIF1AX knockdown. Here, the expression levels for each
gene were first normalized using the trimmed mean of M values (TMM) method [38]. This
approach assumes that most genes are not differentially expressed between samples and identi-
fies a sample-specific scaling factor to allow for more accurate comparisons. Next, we identi-
fied genes whose translational efficiency was affected by the knockdown of EIF1AX.
By this method, 896 genes achieved significance (p-value < 0.05), but only 142 were
deemed to be sufficiently expressed for more detailed analysis (based on whether 50% of the
samples achieved a counts per million (CPM) of> 2 in the RNAseq data; S6 Table). Of these,
nearly all showed reduced translational efficiency—only 7 genes showed increased transla-
tional efficiency following EIF1AX knockdown. These data support the function of EIF1AX as
an initiation factor essential for translation and raise the possibility that certain genes are par-
ticularly susceptible to EIF1AX depletion.
Next, we categorized the genes based on their translational efficiency profiles. The 142
expressed genes that showed differential translational efficiency were grouped into 4 clusters
based on translational efficiency using k-means clustering (Fig 3A). Overall, the genes within a
cluster display a common change in translational efficiency following EIF1AX knockdown
(Fig 3B). Several genes in cluster 1 demonstrate decreased translational efficiencies across all
three cell lines (C20orf24,GET4, GFER, PDF, SAC3D1, and TMEM160). These genes represent
those commonly regulated by wild type and mutant EIF1AX. In contrast, cluster 2 genes show
reduced translational efficiencies in the wild type cell lines (Omm2.3 and Omm1), but no
change in the EIF1AX-mutant cell line (92.1). This cluster includes 26 ribosomal protein genes
(Fig 3B, red). These data indicate that knockdown of wild type EIF1AX results in significantly
suppressed translation of ribosomal proteins, while knockdown of mutant EIF1AX levels does
not.
We were intrigued by the observation that one of the clusters we identified was enriched for
ribosomal protein genes. Translation of ribosomal protein genes is regulated in a coordinated
manner by a 5’ terminal oligopyrimidine tract (5’ TOP) within the mRNA sequence [39]. We
found that the median translational efficiency of all ribosomal protein genes was reduced fol-
lowing EIF1AX knockdown in wild type, but not mutant cells (Fig 3C). This was the only gene
family that exhibited extensive coordinated regulation in the context of EIF1AX knockdown.
In addition, these genes demonstrated already reduced translational efficiency in the mutant
cell line (92.1), and were not additionally affected by EIF1AX knockdown in this setting (Fig
3C). Together, these data raise the possibility that wild type EIF1AX may regulate translation
of ribosomal protein genes, but that this regulation may be diminished in at least some
EIF1AX-mutant settings.
Discussion
In this study, we sequenced the exomes of 52 UM primary tumor/normal pairs. To our knowl-
edge, this represents one of the largest UM cohorts to undergo comprehensive genomic
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characterization to date. Consistent with prior studies, recurrent mutations were observed in
GNAQ, GNA11, BAP1, EIF1AX, and SF3B1 [4,5,13–15]; no additional genes met the threshold
for significance. Based on the observation that the known recurrently mutated gene, SF3B1,
did not reach significance even though 6 mutations were observed by WES, there may have
Fig 3. Decreased EIF1AX expression impairs translation of protein synthesis machinery in wildtype, but not mutated setting. (A)
Principal component analysis depicts 4 color-coded clusters of 141 genes. (B) The trend in translational efficiency is depicted for each
cluster in cells expressing control shRNAs (CN) or EIF1AX shRNAs (KD). Each line represents a different gene. Ribosomal protein genes
are highlighted in red. Translational efficiency was calculated as polysome CPM / total CPM. (C) Boxplots demonstrate the distribution of
the translational efficiencies of 78 ribosomal proteins in cells as in (B).
https://doi.org/10.1371/journal.pone.0178189.g003
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been other mutations that were also missed. This study confirms the relative mutually exclu-
sive nature of BAP1, SF3B1, and EIF1AX gene mutations. Our data further confirm [15,16]
that in contrast to cutaneous melanoma, which has the highest somatic gene mutation fre-
quency of any cancer type [17], UM lacks a UV-radiation mutation signature and has a low
mean somatic mutation rate. Recent data suggest that clinical benefit to immune checkpoint
blockade therapy (e.g., anti-CTLA4) in cutaneous melanoma is associated with higher muta-
tional burden [40]. A higher mutation frequency is thought to generate a diversity of neoanti-
gens that can be recognized by the immune system. Thus, the low somatic gene mutation
frequency observed in this and other UM cohorts may explain the lower response rates thus
far reported for UM tumors using the recently FDA-approved immune checkpoint blockade
inhibitors in cutaneous melanoma [41,42].
In two cases, we sequenced multiple tumors from the same patient. This allowed us to track
enrichment or depletion of specific somatic alterations over the course of disease progression.
To date, monosomy 3 and mutated BAP1 have been associated with UM metastasis [12,13],
but limited analyses of metastatic tumor genomes have been reported. In UM45 in this cohort,
a SMARCA4 mutation was detected in the metastatic sample. SMARCA4mutations were
recently reported in metastatic UM tumors, although matched primary tumor DNA was not
sequenced for comparison [43]. Conceivably, then, SMARCA4 may contribute to the estab-
lishment or maintenance of metastatic disease, although functional studies are needed to con-
firm this hypothesis. Some SMARCA4-mutant cancer cells may be sensitive to inhibition of the
second SWI/SNF catalytic subunit [44–46]. If SWI/SNF mutations are recurrently linked to
metastatic disease in UM, the relevance of this synthetic lethal relationship to residual SWI/
SNF complex function may merit additional exploration.
We identified EIF1AX N-terminal tail mutations in approximately 20% of primary UM
tumors, consistent with prior studies [15]. Putative driver mutations in this translation factor
are of interest given that increased protein synthesis is frequently observed in rapidly prolifer-
ating cancer cells. Both upstream signaling pathways and aberrant translation factor expres-
sion contribute to this phenomenon [47]. Indeed, several translation initiation factors that are
overexpressed in human cancer, including EIF4E, EIF4G, EIF3A, EIF3C, and EIF3H may also
contribute to tumorigenesis [48]. Consistent with these general observations, our RNAi knock-
down experiments suggest an essential role for EIF1AX in both wild type and mutant settings.
EIF1AX is the first translation initiation factor reported as recurrently mutated in cancer, and
is significantly mutated in both UM and papillary thyroid carcinoma [27].
Recent ribosome footprinting experiments demonstrate that translation of the protein syn-
thesis machinery is suppressed by pharmacologic inhibition of mTOR, a well-known regulator
of translation [49,50]. We performed RNA sequencing of polysome-associated mRNAs and
observed similar suppression of the translational efficiency of ribosomal proteins following
EIF1AX knockdown in wild type EIF1AX cells. In contrast, mutant EIF1AX cells did not dis-
play this phenotype. There are at least two possible explanations for these observations. First,
the level of knockdown achieved may not be sufficient to impair mutant EIF1AX function
(thus, ribosomal proteins continue to be translated sufficiently by this mechanism). This
model could be operant if mutated EIF1AX has enhanced function over wild type. However,
the observed 80S accumulation following shRNA expression is consistent with the notion that
the magnitude of EIF1AX knockdown achieved here is functionally consequential. Second,
translation in the setting of mutant EIF1AX may be less efficient overall, such that knockdown
does not further impair ribosomal functions. This model is supported by the higher 80S peak
observed in mutant EIF1AX cells in comparison to wildtype (Fig 2D). This model may also
imply that mutant EIF1AX harbors previously unrecognized yet essential functions that may
or may not be related to translation. For example, one could posit a neomorphic role for
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EIF1AX, resulting in regulation of a unique set of mRNAs or a translation-independent activ-
ity contributing to clonal advantage. However, no evidence for such a neomorphic effect cur-
rently exists. As EIF1AX mutations are associated with a low risk of developing metastatic
disease, additional functional studies are required to determine the specific mechanisms by
which EIF1AX mutations provide a selective advantage to UM cells in which they are present.
In summary, this study utilized systematic genomic approaches to probe the somatic genet-
ics of primary and metastatic UM, as well as the function of mutated EIF1AX. This is the first
study of deregulated translation by a mutated initiation factor in cancer. Future work should
focus on further developing approaches to target the described genetic lesions, in particular in
patients with metastatic potential.
Materials and methods
Tumor specimens
This study was approved by the institutional review boards of the Massachusetts Eye and Ear
Infirmary, MD Anderson Cancer Center, Dana-Farber Cancer Institute, and the Broad Insti-
tute. All patients provided written informed consent. Biopsy samples were obtained from 62
patients with UM. Primary tumor samples were from enucleated eye specimens, while meta-
static samples were from core biopsies obtained by interventional radiology. Fresh tissue was
immediately flash frozen at -80˚C.
DNA extraction and whole exome sequencing
Germline DNA was isolated from peripheral blood (N = 26) or adjacent normal choroidal tis-
sue (N = 35). Detailed sequencing and analysis methods are in Supplementary Material (S1
File). Sequencing data will be deposited in dbGaP (http://www.ncbi.nlm.nih.gov/gap) (acces-
sion # phs001370.v1.p1).
Cell lines
92.1, Mel202, Mel270, Omm2.3, Omm2.5, Omm1, and Mel285 were kindly provided by Mar-
tine Jager in 2011 (Leiden University, The Netherlands). The origins of these cell lines were
previously described [51]. Cells were maintained in RPMI-1640 with 10% heat-inactivated
FBS and identity confirmed by fingerprinting using the GenePrint 10 kit (Promega) in January
2014. An EIF1AX mutation in exon 1 or 2 was observed in only the 92.1 cell line of the 7 lines
tested.
Lentiviral infections of shRNAs
shRNA expression constructs were obtained from The RNAi Consortium of the Broad Insti-
tute in the lentiviral expression plasmid pLKO.1 and include:
shLuc (TRCN0000072243, 5’-CTTCGAAATGTCCGTTCGGTT-‘3)
sh1AX 18 (TRCN0000062618, 5’-CCGAGACTACCAGGATAACAA-3’)
sh1AX 21 (TRCN0000062621, 5’-CCTGGAGATGATGATGAAATT-3’)
Lentivirus was produced by transfecting 2.4e6 293T cells with 3μg pLKO.1, 2.7μg Δ8.9 (gag,
pol), and 0.3μg VSV-G plasmids in the presence of 18μL Xtreme Gene 9 (Roche). Virus was
harvested 72h after transfection and filtered using a 0.45μm syringe. For shRNA expression,
cells were seeded at 2 to 4 x 105 cells/well in 6-well plates for immunoblot assays and polysome
profiling and 1 to 2 x 103 cells/well in 96-well plates for cell viability assays. Cells were infected
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24h later (1:40–1:50) in the presence of polybrene (Millipore; 5μg/mL) and then centrifuged at
2,250 RPM for 30 minutes at 37˚C followed by a media change. To confirm infection effi-
ciency, puromycin (1μg/mL) was added 24h after infection to half the 96-well plate. For poly-
some profiling, cells were passaged into 10cm dishes 24h prior to harvesting.
Viability assays
Cells were infected in 96-well format (as described). Fresh media was added 72h after shRNA
infection and proliferation was assessed in triplicate after another 72h (6 days total) using Cell-
Titer96 Aqueous assay (Promega). Viability was calculated as a percentage of the control
(shLuc) after background subtraction.
Immunoblot analysis
Cells were washed twice with cold PBS and lysed in RIPA buffer containing Halt protease and
phosphatase inhibitor single-use cocktail (Pierce). Lysates were quantified using Bradford
assay (Bio-Rad), resolved by SDS gel electrophoresis (Invitrogen), transferred to nitrocellulose
(Invitrogen) or PVDF (Millipore) membranes, and then blocked with 5% milk and probed
with primary antibodies for EIF1AX (Pierce 1:1,000) and Vinculin (Calbiochem 1:5,000).
HRP-linked secondary antibodies (anti-rabbit, anti-mouse IgG; 1:2,000 dilution, Santa Cruz)
followed by chemiluminescence (Pierce) were used for detection.
Polysome fractionation and RNA isolation
Sub-confluent cells were treated with 100μg/mL cycloheximide for 3 minutes at 37˚C and then
washed twice with cold PBS containing 100μg/mL cycloheximide. Cells were lysed in buffer
(5mM Tris (pH7.4), 2.5mM MgCl2, 1.5mM KCl, 2mM DTT, 0.5% Triton-X, 0.5% NaDOC,
0.1units/μL RNasin, 100μg/mL cycloheximide, and 1x Halt protease and phosphatase inhibitor
single-use cocktail), and then incubated on ice (20 min) and centrifuged at 13,000 RPM (10
min; 4˚C). Lysates were quantified using Abs260 and equal amounts were loaded onto 12mL
10%-50% sucrose gradients (15mM Tris (pH7.4), 15mM MgCl2, 150mM NaCl, 100μg/mL
cycloheximide). Gradients were centrifuged at 35,000 RPM for 2 hours at 4˚C (SW40Ti rotor)
and then 1mL fractionated with Auto Densi-Flow connected to RediFrac with monitoring of
absorbance at 254nm. RNA was extracted from input lysate and polysome fractions using Tri-
zol LS (Invitrogen) and standard phenol/chloroform extraction methods followed by an iso-
propanol precipitation. Pellets from polysome fractions were pooled and an additional ethanol
precipitation was performed.
RNA sequencing and analysis
The Quant-iT RiboGreen RNA Assay Kit (Invitrogen) was used to quantify RNA. cDNA
library construction was performed using the TruSeq RNA Sample Preparation protocol (Illu-
mina, Revision A, 2010). Additional details are provided in Supplementary Material (S1 File).
For analysis, read counts for each gene were used to normalize the data using the TMM
method [38]. Genes whose translation efficiency was affected by the knockdown of EIF1AX
were then identified using the edgeR package [52]. To this end, we fitted the following general-
ized linear model, based on a negative binomial distribution, after estimating the expression
Genomic studies of uveal melanoma
PLOS ONE | https://doi.org/10.1371/journal.pone.0178189 June 8, 2017 12 / 17
level-detrended and gene-wise overdispersion.
counti  ai  cell lineþ bi  replicateþ gi  knockdownþ di  fractionþ Wi  knockdown
 fractionþ εi
where:
counti is the normalized gene counts for gene i
cell line is the vector representing the cell line effect (levels = 92.1, Omm2.3, Omm1)
replicate is the vector representing the replicate experiments (two independent replicate
experiments performed)
fraction is the vector representing the profiling of total or polysomal RNA
The interaction effect zi
knockdownfraction models genes with transcripts that display a
shift in the ratio between the polysomal and total RNA fraction (= translational efficiency)
upon EIF1AX suppression. The genes of interest have a coefficient zi significantly different
from zero. Genes were nominated based on an interaction p-value threshold of 0.05 and an
expression threshold of at least 50% of the samples containing a counts per million (CPM)
greater than 2. Genes were then grouped by a k-means clustering of the translational efficien-
cies using correlation-based (Pearson correlation) similarity measures. One gene was removed
due to division by 0 CPM (XKR6). Four clusters were identified and the trend in the transla-
tional efficiencies across control and knockdown samples for each cell line was depicted.
Translational efficiencies were defined as polysome CPM / total CPM. The average transla-
tional efficiency for control and knockdown was computed and graphed using line plots.
Supporting information
S1 File. Supplementary materials and methods.
(DOC)
S1 Table. Sequencing metrics of 52 uveal melanomas.
(XLS)
S2 Table. Clinical characteristics of 52 uveal melanomas.
(XLS)
S3 Table. All somatic alterations identified by whole exome sequencing in 52 pairs.
(XLS)
S4 Table. Validation of selected mutations by targeted resequencing.
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S5 Table. All somatic alterations identified in trio analysis.
(XLS)
S6 Table. Genes with significant changes in translational efficiency following EIF1AX
knockdown. P-value and cluster is indicated for each gene.
(XLS)
S1 Fig. Copy number profiles of 52 uveal melanomas. Coverage values from whole exome
sequencing were converted into segmentation files and visualized using IGV. Samples are
ordered by chromosome 3 status, or labeled Indeterminate (Ind.) due to noise across the
genome. 1AX indicates samples with an EIF1AX mutation.
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S2 Fig. Kaplan-Meier analysis of recurrent alterations in cohort. (A and B) Kaplan-Meier
analysis showing primary uveal melanoma patients with evaluable OS data who had either
monosomy 3 (n = 20) or disomy 3 (n = 23) tumors. OS reflective of death from metastatic
uveal melanoma; the median survival was 1216 days in the monosomy 3 cohort and not
reached in the disomy 3 cohort. Log-rank p value = 0.0034. HR = 6.9, 95% Cl (1.7 to 15.5)
(B) As in (A), but overall survival reflective of death from any cause; the median survival was
1008 days in the monosomy 3 cohort and not reached in the disomy 3 cohort. Log-rank
p value = 0.0034. HR = 4.5, 95% Cl (1.6 to 10.3). (C) Kaplan-Meier analysis showing primary
uveal melanoma patients with evaluable OS data with tumors harboring a BAP1 (n = 14) vs.
SF3B1 or EIF1AX (n = 14) mutation. OS reflective of death from metastatic uveal melanoma;
the median survival was 744 days in the BAP1 mutant cohort and not reached in the SF3B1/
EIF1AX mutant cohort. The Log-rank p value = 0.0008. HR = 13.7, 95% Cl (3.0 to 62.9). (D)
As in (C), but OS reflective of death from any cause; the median survival was 744 days in the
BAP1 mutant cohort and not reached in the SF3B1/EIF1AX mutant cohort. The Log-rank p
value = 0.0022. HR = 7.5, 95% Cl (2.1 to 28.8). Note, sample UM 36 had both BAP1 and SF3B1
mutations, but was analyzed as a BAP1 mutant sample.
(PDF)
S3 Fig. Trio mutation validation and clinical timeline. (A) IGV screenshot of SMARCA4
mutation from exome sequencing and targeted validation of UM45. (B) Trio 2 biopsy and
treatment are indicated across time course.
(PDF)
S4 Fig. EIF1AX sequence and protein expression across UM cell lines. (A) Exon 2 sequenc-
ing trace displays putative EIF1AXG6D mutation in 92.1 cell line. (B) Immunoblot analysis of
EIF1AX protein levels.
(PDF)
S5 Fig. EIF1AX dependency across 216 cell lines from Project Achilles. (A) Histograms rep-
resent shRNA level scores (normalized log fold change) for 5 EIF1AX (top) and 5 RPS6 (bot-
tom) shRNAs from 216 cell lines in Achilles v2.4.3. Lower values represent more depletion
indicating more dependency. EIF1AX shRNAs used in this study are bolded. (B) Immunoblot
analysis of EIF1AX protein levels in 2 uveal melanoma cell lines expressing indicated shRNAs.
(PDF)
S6 Fig. EIF1AX sequence and expression levels from polysome profiling RNAseq. (A) IGV
screenshot of EIF1AX exon 2 start indicates exclusive mRNA expression of the G6D variant in
the 92.1 cell line. (B) Heatmap displays EIF1AX expression levels in RPKM for total and poly-
some-associated mRNA in 92.1 cells expressing indicated shRNAs. (C) As in (B), but for
Omm2.3 and Omm1 EIF1AX-wild type cells.
(PDF)
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